
Lundback swallows migraine drug maker Alder
Alder's first-in-class monoclonal antibody for migraine prevention, eptinezumab, targets the calcitonin gene-related peptide and faces FDA...

AMR: ENABLE selects Mutabilis candidate
Efficacy of beta-lactam antibiotics, which represent 65% of the antibiotics sold throughout the world, is increasingly challenged in Gram-negative...

BioVersys receives up to €8m from CARB-X
Privately-owned BioVersys AG, headquartered in Basel, is focusing on research and development of small molecules for multidrug-resistant bacterial...

Versantis raises CHF16m in Series B financing
The CHF16m Series B financing was led by Swisscanto Invest by Zürcher Kantonalbank with co-financing by Esperante Venture, investiere, Redalpine...

BASF broadens biotech business by Isobionics acquisition
The acquisition of Isobionics BV (Geleen, The Netherlands) gives the the German world chemistry leader a foothold in the growing US$20.75bn market...

Pharvaris BV raises $66m to advance oral HAE drug
The Series B financing was led by Foresite Capital. New investors Bain Capital Life Sciences, venBio and Venrock, as well as the investors of a €15m...

iStar Medical SA raises €40.1m
Earlybird and BNP Paribas Fortis Private Equity and existing shareholders including Capricorn Partners, Walloon Region Investment Fund (SRIW) and...